ClinicalTrials.gg
Active, not recruitingNCT07105488COMPASS 2-ADUpdated Jul 30, 2026

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of BFB759 and Placebo in Atopic Dermatitis (AD), sponsored by Bluefin Biomedicine, Inc.. Active, not recruiting at 88 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Bluefin Biomedicine, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
154th of 544
225 · median 96
Started
2025
with 40 others
Phase 2
202 of 639
18 open now
Primary completion
2027-02
later than 37 of 115 live
Registered
596th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 154th largest by planned enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 202 in phase 2, reaches primary completion later than 37 of the 115 other live ones, and was the 596th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

03

Conditions studied

  • Atopic Dermatitis (AD)

Keywords

  • Atopic Dermatitis
  • Eczema
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
  • Have moderate to severe disease not adequately controlled by topical treatments.
  • Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.

Exclusion criteria

Exclusion Criteria:

  • Have certain infections or other immune conditions.
  • Recently used medications that could interfere with the study.
  • Are pregnant or breastfeeding.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    Active - high dose

    BFB759 high dose Day 1 followed by BFB759 every 2 weeks (Q2W) starting at Week 2 through Week 14 (inclusive), which is followed by placebo Q2W at Weeks 16 through 30 (inclusive)

    Biological: BFB759

  • Placebo comparator
    Placebo

    Placebo Q2W for 14 weeks. At Week 16, participants in Placebo group who are still enrolled in the study and receiving treatment will be re-randomized (1:1) into two groups (Cross-1 or Cross-2) to receive BFB759 intervention. * Cross-1 will receive BFB759 at Week 16, and then BFB759 Q2W at Week 18 through Week 30 (inclusive). * Cross-2 will receive BFB759 at Week 16, and then BFB759 Q2W at Week 18 through Week 30 (inclusive).

    Biological: BFB759 · Drug: Placebo

  • Experimental
    Active - low dose

    BFB759 low dose on Day 1 followed by BFB759 every 2 weeks (Q2W) starting at Week 2 through Week 14 (inclusive), which is followed by placebo Q2W at Weeks 16 through 30 (inclusive)

    Biological: BFB759

Interventions

  • BiologicalBFB759

    BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis

  • DrugPlacebo

    Placebo for BFB759

06

What researchers measure

Primary outcomes

  1. Efficacy of BFB759 in AD

    To evaluate the efficacy of BFB759 in adult male and female participants with AD as assessed by Eczema Area and Severity Index (EASI) score. Measure improvements in redness, swelling, scratching damage, and roughness.

    Time frame: week 16 and week 32

Secondary outcomes

  1. How well the treatment works at Week 16

    * How many participants had at least a 50%, 75%, or 90% improvement in their eczema signs. * How much the severity and size of eczema-affected areas improved. * Whether participants felt less itchy. * How many participants had a drop of 4 or more points in their itch score (especially for those who started with a higher itch level).

    Time frame: Week 16

  2. How well the treatment works at week 32

    * How much eczema signs changed from Week 16. * How many participants had a 50%, 75%, or 90% improvement since Week 16. * Changes in eczema severity and itch compared to Week 16. * How many people had a 4-point drop in their itch score (again, only among those who had higher itch scores at Week 16).

    Time frame: Week 32

  3. Safety and tolerability

    * record side effects and severity * record how well participants tolerate the treatment over time

    Time frame: 21 months (about 22 visits during the course of study)

07

Study locations

88 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 19 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 6, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Mar 31, 2027
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07105488
Lead sponsor
Bluefin Biomedicine, Inc.
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Jul 15, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion